|
Volumn 45, Issue 12, 2001, Pages 3663-3668
|
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
AMPRENAVIR;
CYTOCHROME P450 3A4;
INDINAVIR;
NELFINAVIR;
PROTEINASE INHIBITOR;
SAQUINAVIR;
AREA UNDER THE CURVE;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG FORMULATION;
DRUG SAFETY;
DRUG TOLERABILITY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MULTICENTER STUDY;
NONHUMAN;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
STEADY STATE;
ADULT;
AREA UNDER CURVE;
CARBAMATES;
CD4 LYMPHOCYTE COUNT;
CYTOCHROME P-450 ENZYME SYSTEM;
DRUG INTERACTIONS;
ENZYME INHIBITORS;
FEMALE;
HIV PROTEASE INHIBITORS;
HIV SEROPOSITIVITY;
HUMANS;
INDINAVIR;
MALE;
MIXED FUNCTION OXYGENASES;
NELFINAVIR;
OROSOMUCOID;
SAQUINAVIR;
SULFONAMIDES;
|
EID: 0035180518
PISSN: 00664804
EISSN: None
Source Type: Journal
DOI: 10.1128/AAC.45.12.3663-3668.2001 Document Type: Article |
Times cited : (21)
|
References (24)
|